Seeking AlphaSat, 09 May 2026 01:51:14 GMTInflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases TranscriptIFRX-2.64%
MarketBeatFri, 08 May 2026 20:04:36 GMTInflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease PipelineIFRX-2.64%
Zacks Investment ResearchThu, 19 Mar 2026 13:46:10 GMTInflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue EstimatesIFRX-2.64%